Company Overview and News

 
Sensex, Nifty turn choppy on mixed global cues

9h freepressjournal.in
Mumbai: Domestic equities opened on a choppy note today tracking mixed cues from other Asian markets, ahead of F&O expiry later this week. The benchmark BSE Sensex, which had lost 11.71 points in the previous session on Friday, rose 78.11 points, only to turn negative within minutes of session opening. The 30-share index was trading 15.24 points, or 0.04 per cent, lower at 34,400.34, with metals and banking stocks leading the losses.
Upvote Downvote

 
Firms in BSE auto index likely to post robust Q4 results

16h livemint
Mumbai: Automobile companies are set to report strong revenue and operating profit growth in the March quarter because of a revival in rural demand and a low-base effect following the negative impact of demonetisation that lasted well into the fourth quarter of the previous financial year.
Upvote Downvote

 
Sensex falls over 50 points on negative global cues, weak rupee

2018-04-20 freepressjournal.in
Mumbai: The benchmark BSE Sensex declined by about 80 points in early session today, in tandem with weak global cues amid rupee’s plunge below the 66 mark. Besides, the release of the minutes of last Monetary Policy Committee (MPC) meeting on April 4-5, indicating the Reserve Bank of India may shift to a hawkish monetary stance in June, weighed on investor sentiment.
Upvote Downvote

 
Varroc to continue focus on growing core business post IPO

2018-04-19 livemint
Mumbai: Auto components maker Varroc Engineering Ltd, which is in the process of launching its initial public offering (IPO), will focus on expanding its two largest verticals—exterior lighting systems for passenger cars and two-wheeler components—after it goes public, managing director Tarang Jain said.
Upvote Downvote

 
Bajaj launches new Pulsar 150 Twin Disc

2018-04-18 moneycontrol
Bajaj Auto today said it has launched its new Pulsar 150 with twin disc brakes priced at Rs 78,016 (ex-showroom – Delhi).
Upvote Downvote

 
Closing Bell: Sensex, Nifty close lower; banks drag but FMCG stocks support

2018-04-18 moneycontrol
3:30 pm Market Closing: Benchmark indices closed lower for the first time in last 10 consecutive sessions, dragged by banks. However, the upside in ITC capped losses.
Upvote Downvote

 
Market Live: Sensex erases gains, Nifty below 10,550; banks under pressure

2018-04-18 moneycontrol
1:55 pm Earnings: Mastek's Q4 consolidated net profit increased to Rs 19.4 crore from Rs 18.4 crore and revenue grew by 6.8 percent to Rs 223.7 crore on sequential basis.
Upvote Downvote

 
Market Live: Sensex extends gains, Nifty inches towards 10,600; ITC leads

2018-04-18 moneycontrol
1:18 pm Market Update: Benchmark indices extended gains in afternoon trade, with the Nifty inching towards 10,600 levels on hopes of strong earnings growth.
Upvote Downvote

 
Market Live: Nifty holds 10,550; FMCG index up 2%, Bharti Group stocks gain

2018-04-18 moneycontrol
12:55 pm Earnings Outlook: "We are looking at Sensex earnings. In Q4, earnings will grow in the range of 13-14 percent, which will be double digit growth after a long time. Partially, this will be due to low base of Q4 last year and the other due to better earnings of global commodity companies, be it energy or metals. That will aid overall growth,” Gaurav Dua, Head of Research, Sharekhan told Moneycontrol.
Upvote Downvote

 
Market Live: Sensex near day#39;s high; ITC top gainer, Zee Entertainment lifts Media index 1.5%

2018-04-18 moneycontrol
11:50 am Buzzing: Federal Bank gained more than a percent after Reliance Securities said it has a Buy rating on the stock with a target price of Rs 150, implying a 51 percent potential upside.
Upvote Downvote

 
Market Live: Sensex consolidates after 9-day gains; hotels stocks extend rally

2018-04-18 moneycontrol
10:55 am Should gold be a part of your portfolio?: Akash Jain, Vice President - Equity Research, Ajcon Global said gold is better as a short to medium-term investment, as long-term returns on the yellow metal are often as low as 10 percent per annum. We would suggest investors not to make too heavy or long-term investments in gold.
Upvote Downvote

 
Sensex extends gains on normal monsoon forecast

2018-04-17 freepressjournal.in
Mumbai: Extending its rising streak for the ninth session, the benchmark BSE Sensex advanced nearly 100 points in opening trade today, after forecast of a normal monsoon for the year.
Upvote Downvote

 
Sensex surges over 200 pts, Nifty above 10,500

2018-04-14 freepressjournal.in
Mumbai: The BSE benchmark Sensex surged over 200 points in afternoon trade today amid buying in most sectors, reflecting positive investor sentiment on strong macroeconomic numbers released yesterday.
Upvote Downvote

 
Sensex rises over 100 points on positive macro data

2018-04-13 freepressjournal.in
Mumbai: The benchmark Sensex gained over 100 points in early trade today, continuing its rising streak for the seventh straight session on the back of positive macroeconomic data, ahead of Infosys earnings later in the day.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...